Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 16/20 | 0.59 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16035344 | 0.88 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL11049 | 0.86 | PIK3CD (0.71) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL8581 | 0.84 | PIK3CD (0.83) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL18800181 | 0.83 | PIK3CD (0.62) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL11923484 | 0.82 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL11832 | 0.82 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL11360 | 0.82 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL15235649 | 0.82 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL10935 | 0.81 | PIK3CD (0.66) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB | |
| SCHEMBL19520470 | 0.80 | PIK3CG (0.43) | PIK3CDPIK3CGPIK3R1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028959-B2 | Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors | RESPIVERT LTD. (GB) | 2018-07-24 | — | — | US | disclosed |
| US-10028959-B2 | Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors | RESPIVERT LTD. (GB) | 2018-07-24 | — | — | US | disclosed |
| US-10028959-B2 | Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors | RESPIVERT LTD. (GB) | 2018-07-24 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170202841-A1 | QUINAZOLIN-4 (3H)-ONE DERIVATIVES USED AS P13 KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
| US-20140249164-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2014-09-04 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| EP-2491037-B1 | QUINAZOLIN-4(3H)-ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2012052753-A1 | QUINAZOLIN-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2012-04-26 | — | — | WO | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028959-B2 | Quinazolin-4 (3H)-one derivatives used as P13 kinase inhibitors | MAP3K13, IRAK3, MAP3K3 | PIK3CD 137/4885PIK3CG 171/4885PIK3R1 447/4885 |
| US-20140249164-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CD 4224/4885PIK3CG 3708/4885PIK3R1 4842/4885 |
| US-20170202841-A1 | QUINAZOLIN-4 (3H)-ONE DERIVATIVES USED AS P13 KINASE INHIBITORS | MAP3K13, IRAK3, MAP3K3 | PIK3CD 137/4885PIK3CG 171/4885PIK3R1 447/4885 |
| US-20120208799-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CD 4224/4885PIK3CG 3708/4885PIK3R1 4842/4885 |
| US-20180118754-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | PIK3CD 4224/4885PIK3CG 3708/4885PIK3R1 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.